STAAR SURGICAL CO
STAANasdaqHealthcare · Ophthalmic Goods · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY26 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $239.4M | $313.9M | $322.4M | $284.4M | $22.1M | $20.9M |
| Operating income | −$91.7M | −$12.6M | $28.1M | $43.8M | $6.8M | $11.9M |
| Net income | −$80.4M | −$20.2M | $21.3M | $38.8M | $5.9M | $14.0M |
| Total assets | $451.7M | $509.5M | $488.7M | $414.9M | $345.8M | $207.5M |
| Total liabilities | $107.5M | $112.2M | $102.7M | $82.7M | $87.2M | $47.6M |
| Equity | $344.2M | $397.3M | $386.0M | $332.2M | $197.2M | $159.9M |
| EPS (diluted) | $-1.62 | $-0.41 | $0.43 | $0.78 | $0.12 | $0.30 |
| Shares out. | 49.5M | 48.9M | 48.2M | 47.8M | 46.6M | 45.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2026- Operating margin
- −38.3%
- Net margin
- −33.6%
- Return on equity
- −23.4%
- Return on assets
- −17.8%
- Return on capital (ROCE)
- −23.9%
- Liabilities / assets
- 23.8%
- Debt / equity
- 0.31×
- Book value / share
- $6.95
- Revenue growth (YoY)
- −23.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2026- Altman Z″ (distress)
- 4.46safe
- Accruals / assets
- −10.2%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Andrews Deborah JOfficer — Interim Co-CEO and CFO | May 15, 2026 | Grant | 10,466 | $0.00 |
| Foust WarrenOfficer — Interim Co-CEO and Pres. & COO | May 15, 2026 | Grant | 14,662 | $0.00 |
| Michna MagdaOfficer — Chief Development Officer | May 15, 2026 | Grant | 10,997 | $0.00 |
| Foust WarrenOfficer — Interim Co-CEO and Pres. & COO | May 8, 2026 | Tax withholding | 3,448 | $26.69 |
| Michna MagdaOfficer — Chief Development Officer | May 8, 2026 | Tax withholding | 1,680 | $26.69 |
| Foust WarrenOfficer — Interim Co-CEO and Pres. & COO | Mar 12, 2026 | Option exercise | 8,175 | $0.00 |
| Michna MagdaOfficer — Chief Development Officer | Mar 12, 2026 | Option exercise | 6,178 | $0.00 |
| Broadwood Partners, L.P.Director | Mar 11, 2026 | Buy | 54,764 | $17.52 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.9M | 4.9 | -12.5% |
| Apr 30, 2026 | 6.7M | 9.2 | -10.2% |
| Apr 15, 2026 | 7.5M | 4.7 | -3.0% |
| Mar 31, 2026 | 7.7M | 5.6 | +10.2% |
| Mar 13, 2026 | 7.0M | 6.0 | +12.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 13, 2026
- Regulation FD disclosureApr 8, 2026
- Results of operations · Regulation FD disclosureMar 3, 2026
- Director / officer changeFeb 5, 2026
- Director / officer change · Regulation FD disclosureFeb 2, 2026
- Director / officer changeJan 16, 2026
- Entered a material agreement · Delisting / listing-standard notice · Director / officer change · Other material eventJan 15, 2026
- Terminated a material agreement · Shareholder voteJan 6, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4May 19, 2026
- 4May 19, 2026
- 4May 19, 2026
- 10-QMay 13, 2026
- 8-KMay 13, 2026
- SCHEDULE 13GMay 12, 2026
- 4May 12, 2026
- 4May 12, 2026
- ARSMay 4, 2026
- DEFA14AMay 4, 2026
- DEF 14AMay 4, 2026
- SCHEDULE 13G/AApr 24, 2026
- SCHEDULE 13GApr 20, 2026
- 8-KApr 8, 2026
- SCHEDULE 13G/AMar 27, 2026